PYY and obesity disorder: Pharmacologic GLP-1RA administration has been shown to have various reductions in food consumption scores and an increase in perceived fullness in humans with obesity, where postprandial plasma levels of GLP-1 decreased and peptide YY (PYY) levels increased with the GLP-1RA liraglutide [130].